TerminatedPhase 2NCT02504892
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Studying Birt-Hogg-Dubé syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramaprasad Srinivasan, M.D., M.DNational Cancer Institute (NCI)
- Intervention
- Everolimus(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2015 – 2018
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02504892 on ClinicalTrials.govOther trials for Birt-Hogg-Dubé syndrome
Additional recruiting or active studies for the same condition.